Protéines associées aux CRISPR : Questions médicales fréquentes
Nom anglais: CRISPR-Associated Proteins
Descriptor UI:D064130
Tree Number:D12.776.212
Termes MeSH sélectionnés :
Government Programs
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéines associées aux CRISPR : Questions médicales les plus fréquentes",
"headline": "Protéines associées aux CRISPR : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéines associées aux CRISPR : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-15",
"dateModified": "2025-05-10",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéines associées aux CRISPR"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines",
"url": "https://questionsmedicales.fr/mesh/D011506",
"about": {
"@type": "MedicalCondition",
"name": "Protéines",
"code": {
"@type": "MedicalCode",
"code": "D011506",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Protéine-9 associée à CRISPR",
"alternateName": "CRISPR-Associated Protein 9",
"url": "https://questionsmedicales.fr/mesh/D000076987",
"about": {
"@type": "MedicalCondition",
"name": "Protéine-9 associée à CRISPR",
"code": {
"@type": "MedicalCode",
"code": "D000076987",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.212.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Protéines associées aux CRISPR",
"alternateName": "CRISPR-Associated Proteins",
"code": {
"@type": "MedicalCode",
"code": "D064130",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yi Zhang",
"url": "https://questionsmedicales.fr/author/Yi%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China."
}
},
{
"@type": "Person",
"name": "Yue Feng",
"url": "https://questionsmedicales.fr/author/Yue%20Feng",
"affiliation": {
"@type": "Organization",
"name": "Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China. Electronic address: fengyue@mail.buct.edu.cn."
}
},
{
"@type": "Person",
"name": "Joseph Bondy-Denomy",
"url": "https://questionsmedicales.fr/author/Joseph%20Bondy-Denomy",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94143, USA."
}
},
{
"@type": "Person",
"name": "Alan R Davidson",
"url": "https://questionsmedicales.fr/author/Alan%20R%20Davidson",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada; Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A8, Canada. Electronic address: alan.davidson@utoronto.ca."
}
},
{
"@type": "Person",
"name": "Xu Peng",
"url": "https://questionsmedicales.fr/author/Xu%20Peng",
"affiliation": {
"@type": "Organization",
"name": "Department of Biology, University of Copenhagen, Copenhagen N, Denmark. Electronic address: peng@bio.ku.dk."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Assessing the interactions of people and policy-makers in social participation for health: an inventory of participatory governance measures from a rapid systematic literature review.",
"datePublished": "2023-11-17",
"url": "https://questionsmedicales.fr/article/37978389",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12939-023-01918-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effectiveness of a course on family health in the knowledge of doctors of the Mais Médicos program.",
"datePublished": "2023-01-09",
"url": "https://questionsmedicales.fr/article/36629652",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/1806-9282.20220966"
}
},
{
"@type": "ScholarlyArticle",
"name": "Implementation and Evaluation of an Interprofessional Health Systems Science Professional Development Program.",
"datePublished": "2023-01-06",
"url": "https://questionsmedicales.fr/article/36634613",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/ACM.0000000000005144"
}
},
{
"@type": "ScholarlyArticle",
"name": "Rethinking communications for governance of malaria programs.",
"datePublished": "2023-07-31",
"url": "https://questionsmedicales.fr/article/37523349",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pgph.0001132"
}
},
{
"@type": "ScholarlyArticle",
"name": "Early Career Outcomes of Embedded Research Fellows: An Analysis of the Health System Impact Fellowship Program.",
"datePublished": "2023-02-22",
"url": "https://questionsmedicales.fr/article/37579439",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.34172/ijhpm.2023.7333"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines associées aux CRISPR",
"item": "https://questionsmedicales.fr/mesh/D064130"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéines associées aux CRISPR - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéines associées aux CRISPR",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéines associées aux CRISPR",
"description": "Comment identifier les protéines CRISPR dans un échantillon ?\nQuels tests sont utilisés pour détecter les protéines associées ?\nPeut-on détecter les protéines CRISPR par imagerie ?\nQuels marqueurs sont spécifiques aux protéines CRISPR ?\nComment évaluer l'activité des protéines CRISPR ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Government+Programs&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéines associées aux CRISPR",
"description": "Quels symptômes sont liés à des dysfonctionnements CRISPR ?\nLes protéines CRISPR causent-elles des effets secondaires ?\nComment les protéines CRISPR affectent-elles la santé ?\nY a-t-il des symptômes d'allergie aux protéines CRISPR ?\nLes protéines CRISPR peuvent-elles provoquer des cancers ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Government+Programs&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéines associées aux CRISPR",
"description": "Comment prévenir les maladies liées aux protéines CRISPR ?\nLes vaccins peuvent-ils intégrer CRISPR ?\nY a-t-il des mesures préventives pour les traitements CRISPR ?\nComment éduquer sur les risques des CRISPR ?\nLes tests génétiques peuvent-ils prévenir des maladies ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Government+Programs&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéines associées aux CRISPR",
"description": "Comment les protéines CRISPR sont-elles utilisées en thérapie ?\nQuels types de maladies peuvent être traités avec CRISPR ?\nY a-t-il des traitements en cours avec CRISPR ?\nQuels sont les défis des traitements CRISPR ?\nCRISPR peut-il être utilisé pour des maladies infectieuses ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Government+Programs&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéines associées aux CRISPR",
"description": "Quelles complications peuvent survenir avec CRISPR ?\nComment gérer les complications des traitements CRISPR ?\nLes complications sont-elles fréquentes avec CRISPR ?\nQuelles sont les conséquences des effets hors cible ?\nLes complications peuvent-elles être réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Government+Programs&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéines associées aux CRISPR",
"description": "Quels sont les facteurs de risque pour les traitements CRISPR ?\nLes mutations génétiques augmentent-elles les risques ?\nL'environnement influence-t-il les risques liés à CRISPR ?\nLes antécédents familiaux sont-ils un facteur de risque ?\nLes traitements antérieurs affectent-ils les risques ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Government+Programs&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les protéines CRISPR dans un échantillon ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par des techniques comme la PCR et le séquençage."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les protéines associées ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'immunobuvardage et de chromatographie peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Peut-on détecter les protéines CRISPR par imagerie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des techniques comme la microscopie à fluorescence peuvent être utilisées."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont spécifiques aux protéines CRISPR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs spécifiques incluent les séquences génétiques uniques des gènes cas."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'activité des protéines CRISPR ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'activité peut être évaluée par des tests de coupure d'ADN et d'édition génétique."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à des dysfonctionnements CRISPR ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes peuvent inclure des anomalies génétiques et des maladies héréditaires."
}
},
{
"@type": "Question",
"name": "Les protéines CRISPR causent-elles des effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires peuvent survenir, comme des réponses immunitaires indésirables."
}
},
{
"@type": "Question",
"name": "Comment les protéines CRISPR affectent-elles la santé ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent influencer la santé en modifiant des gènes liés à des maladies."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes d'allergie aux protéines CRISPR ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réactions allergiques peuvent survenir, mais elles sont rares et peu documentées."
}
},
{
"@type": "Question",
"name": "Les protéines CRISPR peuvent-elles provoquer des cancers ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des modifications génétiques inappropriées peuvent augmenter le risque de cancer."
}
},
{
"@type": "Question",
"name": "Comment prévenir les maladies liées aux protéines CRISPR ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par des dépistages génétiques et des conseils en génétique."
}
},
{
"@type": "Question",
"name": "Les vaccins peuvent-ils intégrer CRISPR ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches explorent l'utilisation de CRISPR pour améliorer les vaccins existants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives pour les traitements CRISPR ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mesures incluent le suivi des effets secondaires et l'évaluation des risques."
}
},
{
"@type": "Question",
"name": "Comment éduquer sur les risques des CRISPR ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation passe par des campagnes d'information et des ressources en santé publique."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils prévenir des maladies ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques permettent d'identifier les risques et de prendre des mesures."
}
},
{
"@type": "Question",
"name": "Comment les protéines CRISPR sont-elles utilisées en thérapie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont utilisées pour corriger des mutations génétiques dans des thérapies géniques."
}
},
{
"@type": "Question",
"name": "Quels types de maladies peuvent être traités avec CRISPR ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "CRISPR peut traiter des maladies génétiques, des cancers et des infections virales."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements en cours avec CRISPR ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, plusieurs essais cliniques explorent l'utilisation de CRISPR pour diverses maladies."
}
},
{
"@type": "Question",
"name": "Quels sont les défis des traitements CRISPR ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les défis incluent la précision de l'édition et les effets hors cible potentiels."
}
},
{
"@type": "Question",
"name": "CRISPR peut-il être utilisé pour des maladies infectieuses ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CRISPR est exploré pour cibler et éliminer des virus dans des infections."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec CRISPR ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des modifications hors cible et des réactions immunitaires."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications des traitements CRISPR ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical rigoureux et des ajustements de traitement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes avec CRISPR ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares mais peuvent survenir, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences des effets hors cible ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets hors cible peuvent entraîner des mutations indésirables et des maladies."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles, mais cela dépend du cas spécifique."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les traitements CRISPR ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, l'état de santé et les antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Les mutations génétiques augmentent-elles les risques ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines mutations peuvent accroître le risque de complications avec CRISPR."
}
},
{
"@type": "Question",
"name": "L'environnement influence-t-il les risques liés à CRISPR ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'environnement peut jouer un rôle dans l'expression des gènes modifiés."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux sont-ils un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies génétiques peuvent augmenter les risques."
}
},
{
"@type": "Question",
"name": "Les traitements antérieurs affectent-ils les risques ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements antérieurs peuvent influencer la réponse aux thérapies CRISPR."
}
}
]
}
]
}
Social participation, also termed stakeholder voice, is an important component of health system governance. Increased interactions between the community and policy makers could facilitate a more respo...
The aim of this study was to analyze the effectiveness of the distance education course in family health in the knowledge of physicians from the Mais Médicos program....
This is a quantitative, quasi-experimental study, without a pretest and posttest control group, carried out from August 2019 to September 2021. In all modules, physicians responded to a pretest and po...
There was a statistically significant difference in all modules with higher average scores in the posttests; the modules with the greatest emphasis are child health care: growth and development; appro...
The effectiveness of the distance education course was verified, as evidenced by the significant improvement of knowledge in all the modules studied....
Few interprofessional development programs focused on learning knowledge and skills in health systems science (HSS) have been described. The authors implemented a professional development program (the...
The HSS Academy (an 8-month active learning classroom and project-based curriculum) was implemented at Penn State College of Medicine in 2015. To create an interprofessional environment, participants ...
From 2015 to 2021, 121 of 128 participants, including physicians, medical students, and nurses, completed the HSS Academy (95% completion rate). Over 90 individuals, including faculty and system leade...
Next steps will be to address financial support for creating and sustaining the HSS Academy, ensure a mutually shared understanding of the HSS Academy's goals among all stakeholders, facilitate meanin...
Malaria has, to a great extent, become normalized and accepted as inevitable. To resume global progress on malaria elimination, national malaria programs in many malaria-endemic countries urgently nee...
This descriptive study reports the early career outcomes of postdoctoral fellows who completed a novel embedded fellowship training program, the Canadian Institutes of Health Research (CIHR) Health Sy...
Employment of fellowship alumni upon completion of the program were tracked using internet searches of publicly accessible online sources and complemented with program survey data....
Descriptive analyses show that all 87 eligible alumni included in the study are currently employed (100% of 87), with 92% employed in Canada. Their employment spans several sectors, including in acade...
We find that HSI Fellow alumni are employed mostly in research-related roles in a range of sectors including, but not limited to academia, that they positively perceive the program's success in elevat...
This article analyzes the Integrated Endemic Disease Program (PIDE), which was established in 1973 by the National Council for Scientific and Technological Development CNPq, financed by the Brazilian ...
We describe awareness about the modified "public charge" rule among Oregon's Mexican-origin Latino/a population and whether concerns about the rule influenced disenrollment from state-funded programs,...
We conducted a cross-sectional survey of adults (ages 18-59) recruited at the Mexican consulate and living in the state of Oregon. Our outcomes were awareness (of the public charge, source of knowledg...
Of 498 Latino/a respondents, 48% reported awareness of the public charge. Among those who knew about the public charge, 14.6% had disenrolled themselves or family members from public healthcare progra...
Our study reveals limited awareness about the public charge among Mexican-origin Oregon Latino/as. Outreach and advocacy are essential to ensure Latino/as know their rights to access available state-f...
In Brazil, there has been an expansion of the coverage of dental services in primary health care (PHC), and the focus of the services has changed to include more efforts in prevention and diagnosis. H...
Improving child and maternal health remains a core objective of global health priorities, extending from the millennium development goal (MDG) era to the current focus on the Sustainable Development G...
A two stage random sample survey of reproductive-aged women residing in treatment and comparison districts at the GEHIP baseline and end line was used for Heckman Difference-in-differences (DiD) regre...
After controlling for child age and gender, maternal age, education, marital status, health insurance status, religion, ethnicity, occupation and household wealth index, regression results show that G...
Previous research has shown that GEHIP had a pronounced positive effect with a reduction in mortality. Our results show that household location in GEHIP districts also led to a significant reduction i...
Iran government implemented the targeted subsidy plan in December 2010 to reduce energy consumption and inequality. In addition, the Health Transformation Plan was implemented by the Ministry of Healt...
In this study, data on 528,046 households were collected using household surveys during 14 years (2007-2020). The Fairness in Financial Contribution index and Catastrophic Health Expenditures index we...
The FFC index was 0.829 and 0.795 respectively in 2007 and 2020. The trend analysis did not show significant changes in the FFC index between 2007 and 2020. TSP and HTP implementations do not reduce h...
The government subsidy programs have not been effective in improving FFC and reducing CHE indices. None of them has been able to realize the goal of the 6th National Development Plan of reducing CHE t...